Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 14/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.60 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.60 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | DHODH | Q02127 | 1/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5835019 | 0.87 | HPSE (1.00) | HPSEKDM4EMEN1POLBDUSP3 | |
| SCHEMBL5834176 | 0.85 | HPSE (0.86) | HPSEKDM4EMEN1POLBDUSP3 | |
| SCHEMBL5835041 | 0.83 | HPSE (0.81) | HPSEKDM4EMEN1POLBDUSP3 | |
| SCHEMBL5834335 | 0.82 | HPSE (1.00) | HPSE | |
| SCHEMBL5835591 | 0.81 | HPSE (1.00) | HPSETP53 | |
| SCHEMBL5834711 | 0.81 | HPSE (0.86) | HPSEKDM4EMEN1POLBDUSP3 | |
| SCHEMBL5834805 | 0.79 | HPSE (0.75) | HPSETP53 | |
| SCHEMBL5834162 | 0.79 | HPSE (0.75) | HPSETP53 | |
| SCHEMBL6738994 | 0.76 | MEN1 (0.69) | HPSEKDM4EMEN1POLBDUSP3 | |
| SCHEMBL9564308 | 0.76 | HSD17B10 (0.72) | HPSEKDM4EMEN1POLBDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138425-B2 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2006-11-21 | — | — | US | claimed |
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2005-09-15 | — | — | US | claimed |
| US-7138425-B2 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2006-11-21 | — | — | US | disclosed |
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2005-09-15 | — | — | US | disclosed |
| EP-1483261-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074516-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, IDH1 | HPSE 2626/4885KDM4E 1348/4885MEN1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.